Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZymeQuest licenses enzyme technology to Life Sciences Company
The licensee has paid ZymeQuest an initial licensing fee of $2 million. In addition, the license agreement provides for the payment of royalties based on production levels of
The licensee has paid ZymeQuest an initial licensing fee of $2 million. In addition, the license agreement provides for the payment of royalties based on production levels of
The Phase II clinical trial is a open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily versus azathioprine (AZA),
All patients have completed their final clinical assessment. The data are being analysed, and results will be delivered in the first quarter of 2008. This Phase IIa trial
The bipolar mania submission is based on a clinical study of once-daily treatment with Seroquel, compared to placebo, with a primary endpoint of change in YMRS (Young Mania
Watson’s Ipratropium Bromide and Albuterol Sulfate product is the generic equivalent to Dey’s DuoNeb, which is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease
Effective immediately, Alliance BMP will account for financial results from its 50% stake in Guangzhou Pharmaceuticals (GP), the third largest pharmaceutical wholesaler in China. The accretive transaction is
The company has received final approval following the expiration of Roche’s patent on December 28, 2007, and plans to launch its product shortly. Kytril (granisetron hydrochloride) tablets, 1mg
The drug is indicated to treat breathing difficulty in patients with chronic obstructive pulmonary disease (COPD). Shipment of the product will begin immediately. The company claims that the
The claims in the suit include breach of confidentiality agreements, conversion of Kinetic Concepts (KCI) technology, theft of trade secrets and conspiracy. KCI is seeking damages and injunctive
Exactech announced the exercise of its option and execution of a merger agreement to acquire Altiva in December, 2007 based on a valuation of $25 million. Exactech’s final